Bacterial Resistance & Infection Control

Bacterial Resistance and Infection Control – Stanford University CF Centre
by Richard Moss, M.D.

Many patients and families are concerned about infection control. First, it is essential to understand what we mean when we talk about resistance of bacteria to antibiotics. What does it really mean? Continue reading “Bacterial Resistance & Infection Control”

Like a hands free nebuliser?

screen-shot-2016-11-01-at-8-30-01-pm

 

 

“At MakerHealth we believe in democratizing the tools of health making around the world. Whether it’s a hospital bed, smart pill bottle, or an improved triage mobile phone app we believe that design should be transparent, hackable, and enabling for everyone to be the designers and makers of their own healthcare solutions.”

Like all industries, health is being disrupted every day by changes and progress in technology. It brings people together, it democratises the flow of information and research,  it  empowers  all parties and with this increased degree of transparency and accountability comes the human urge to connect and to share. To seek out others who might understand where we’re at. To crowdsource ideas and to create community solutions. Maker Health is doing just that.

We believe everyone can be a medical maker. In a world where health care technology is increasingly black boxed, and unaffordable, we found a stealth community of innovators working around the clock to make health better, by making their own devices to make us better.

I recently met up with another mother at the North American Cystic Fibrosis Conference and like all speakers who spark the mind; I stalked her online and found her blog 66 Roses but also a great post where, faced with the prospect of endless nebuliser treatments and hoping to find a solution to a hands free nebuliser, she crowdsourced the idea on Twitter, got back a load of responses and posted it herself on Maker Health to help with others.

Good share.

John Hopkins’ CF research review

If you’re looking to keep abreast of the latest research on key topics, the John Hopkins CF Centre in the US publishes a regular newsletter called e-cysticfibrosis review which basically publishes a peer review of a whole bunch of research into critical care topics.

It’s set up for medical care teams to subscribe to but anyone can join it. They’ve just done a brief summary of pseudomonas research and treatment protocols for anyone who is interested.

If you’re keen, you can sign up here  e-cysticfibrosis review

screen-shot-2016-10-27-at-12-30-10-pm

Could nasal swabs decrease staph?

In a double-blind, placebo controlled, independent clinical study by investigators at the Medical University of South Carolina, Nozin® Nasal Sanitizer® antiseptic was effective in significantly reducing Staph aureus nasal carriage in health care providers (HCPs).  The results demonstrate that the administration of this nonantibiotic antiseptic (Nozin Nasal Sanitizer) was effective in reducing S. aureus and total bacteria in a single-day application protocol.  The publication of the study can be found in the American Journal of Infection Control as a major article titled: Reduction of nasal Staphylococcus aureus carriage in health care professionals by treatment with a nonantibiotic, alcohol-based nasal antiseptic.

Why are these results significant?   It is commonly believed that the primary reservoir for the pathogen Staph aureus is the vestibule of the nose.  Now, it has been shown that carriage can be reduced using a commercially available ethanol based antiseptic, Nozin Nasal Sanitizer.  Additionally, use of this trusted antiseptic will not likely contribute to the rise in antibiotic resistance, an important issue in infection control. As stated in another study on the role of nasal carriage,  “Staphylococcus aureus is a frequent cause of infections in both the community and hospital. Worldwide, the increasing resistance of this pathogen to various antibiotics complicates treatment of S. aureus infections. Effective measures to prevent S. aureus infections are therefore urgently needed. It has been shown that nasal carriers of S. aureus have an increased risk of acquiring an infection with this pathogen. The nose is the main ecological niche where S. aureus resides in human beings…”1

The positive results from the Medical University of South Carolina study published in the American Journal of Infection Control indicate the potential of Nozin Nasal Sanitizer as a tool in helping to reduce infections in healthcare settings, a paradigm that Nozin scientists have been promoting for years. This third party, peer-reviewed validation of the efficacy of Nasal Sanitizer® and Nozaseptin™ technology further supports use of Nozin Nasal Sanitizer® as a safe and effective non-antibiotic treatment.

Read the Clinical trial  here which suggests non antibiotic nasal swabs are a good way to decrease / arrest bacteria colonisation of the nasal passages , especially as it pertains to staph.

 

 

 

A little inspiration for the weekend

‘Up For Air’ explores the human spirit’s fight for survival through the eyes of Jerry Cahill – a 53-year-old pole-vaulter who continues to fight respiratory degeneration, depression and a potentially fatal double-lung transplant. Shot over a period of five years, Up For Air captures the fragility of life with a chronic, fatal illness as it disrupts physical, mental, interpersonal and professional well-being, and how the intersection of dedicated athleticism, self discipline, and community outreach can achieve unprecedented outcomes.

Doesn’t that make you want to put your trainers on and take your kid for a run?

FDA Approves Orkambi for Children, Ages 6-11, with Cystic Fibrosis

shutterstock_117362710-1024x683.jpgVertex Pharmaceuticals reported that the U.S. Food and Drug Administration (FDA) has granted approval for its cystic fibrosis (CF) drug Orkambi to be used to treat children, ages 6 to 11, who have two copies (one inherited from each parent) of the F508del mutation in the CFTR gene.

Continue reading “FDA Approves Orkambi for Children, Ages 6-11, with Cystic Fibrosis”